Integra Lifesciences (IL3) AI Stock Analysis

0 Followers

Integra Lifesciences

(Frankfurt:IL3)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring consumables demandIntegra’s mix of procedure-based consumables, implants and replacement components can create repeat purchasing across neurosurgery, neurocritical care and wound treatment. This recurring demand supports revenue visibility and gives the company a durable base beyond one-time capital equipment sales.

Negative Factors

Elevated leverageThe materially higher leverage leaves Integra with less financial flexibility than in earlier years and increases sensitivity to operating setbacks. Weakened profitability and substantial debt obligations can constrain investment, limit capital allocation choices and prolong the balance-sheet recovery.

Integra Lifesciences (IL3) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.12B
Dividend Yield: ―
Average Volume (3M): 100
Price to Earnings (P/E): 85.0
Beta (1Y): 0.97
Revenue Growth: -4.23%
EPS Growth: ―
Country: Germany
Employees: 4,427
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Integra Lifesciences Business Overview & Revenue Model

Company Description

Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including...

Integra Lifesciences Earnings Call Summary

Earnings Call Date:Oct 21, 2026(Q3-2026)|% Change Since:10.17%|Next Earnings Date:Mar 03, 2027

Earnings Call SentimentNeutral

The call presented meaningful operational and financial progress, including record quarterly operating cash flow, leverage reduction, successful refinancing, improved product availability, strong neurosurgery performance, and several 2027 growth initiatives. However, these positives were balanced by the Cincinnati disruption, reduced revenue and EPS outlooks, Tissue Reconstruction weakness, gross-margin pressure, higher refinancing-related interest expense, and continued competitive and execution challenges. Overall sentiment was balanced, with a constructive long-term outlook but significant near-term headwinds.

Positive Updates

Third-Quarter Revenue and EPS Performance

Third-quarter revenue was $411.2 million, up 2.3% on a reported basis and 2.5% organically, at the low end of guidance. Adjusted earnings per share increased to $0.59 from $0.54 in the prior year, primarily reflecting higher revenue and lower operating expenses from cost-reduction initiatives.

Negative Updates

Cincinnati Flood Disruption

The Cincinnati disruption reduced third-quarter revenue by approximately $7 million, with an additional revenue impact of approximately $15 million-$20 million expected in the fourth quarter. The MAYFIELD product family represents the majority of the remaining revenue headwinds, and full manufacturing operations are not expected to resume until the second quarter of 2027.

Company Guidance

For the fourth quarter, Integra expects revenue of $413 million to $433 million, representing a reported decline of 5.2% to 0.5% and an organic decline of 5.1% to 0.4%, with no material revenue contribution from SurgiMend and an expected $15 million-$20 million Cincinnati impact. For the full year, it continues to expect revenue of $1.634 billion to $1.654 billion, adjusted earnings per share of $2.30 to $2.40, adjusted gross margin to be approximately flat compared with 2025, and operating cash flow of approximately $190 million-$200 million; it expects to end fiscal 2026 just above its target leverage range of 2.5-3.5 times. Tissue Reconstruction revenue is expected to be approximately flat for the full year, while base Tissue Reconstruction is expected to be flat in 2027 versus 2026 and SurgiMend is expected to contribute growth. Cincinnati is expected to return to full manufacturing operations during the second quarter of 2027, with very limited revenue contribution in Q2 2027, a quarterly impact of $15 million to $20 million, and no meaningful back order clearance assumed. For 2027, revenue is expected to grow, EPS is expected to see some growth, incremental interest expense is expected to be $24 million, and transformation savings are expected to contribute an incremental $10 million-$15 million.

Integra Lifesciences Risk Analysis

Integra Lifesciences disclosed 31 risk factors in its most recent earnings report. Integra Lifesciences reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Integra Lifesciences Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:IL3 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SYK	75Outperform	$121.36B	33.11	15.61%	1.13%	7.87%	22.82%
SNN	69Neutral	$12.80B	20.37	12.25%	2.56%	5.26%	31.02%
ZBH	69Neutral	$20.34B	26.36	6.05%	0.92%	6.98%	-2.22%
ENOV	58Neutral	$1.65B	-3.00	-35.53%	―	3.28%	62.02%
CNMD	53Neutral	$1.51B	20.84	7.07%	―	1.93%	16.93%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:IL3 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:IL3	Integra Lifesciences	13.00	2.80	27.45%
ENOV	Enovis Corporation	27.64	-2.35	-7.84%
CNMD	Conmed Corporation	50.48	8.44	20.08%
SNN	Smith & Nephew Snats	31.00	-0.86	-2.69%
SYK	Stryker Corp	312.39	-45.86	-12.80%
ZBH	Zimmer Biomet Holdings	104.56	15.60	17.54%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Integra Lifesciences AI Stock Analysis